The effect of shingles vaccination at different stages of the dementia disease course.
Level 3 - non-randomized controlled study
Quasi-experimental natural experiment (regression discontinuity cohort design)
PubMed 41338191 · doi:10.1016/j.cell.2025.11.007
What was done
The authors conducted a natural experiment in Wales leveraging a strict age-eligibility threshold for the live-attenuated herpes zoster (HZ) vaccination program. Individuals turning 80 just after the program launch date were vaccine-eligible for one year, whereas those turning 80 just before were ineligible for life. The study evaluated subsequent diagnoses of mild cognitive impairment (MCI), dementia subtypes, and dementia-related mortality among individuals living with dementia.
What was found
The abstract reports no numerical values, relative risks, or confidence intervals. It states qualitatively that live-attenuated HZ vaccination reduced MCI diagnoses, reduced deaths due to dementia among those already diagnosed, and that exploratory analyses indicated the effects were not driven by a specific dementia subtype.
Why it matters
This study extends prior evidence of shingles vaccination preventing dementia onset by suggesting it may also protect against milder pre-dementia cognitive impairment and slow progression or mortality in existing dementia.
Limits
The abstract provides no sample size, effect sizes, p-values, or confidence intervals. The study evaluates the older live-attenuated vaccine rather than the current recombinant vaccine, relies on diagnostic coding in registry data, and findings are derived from a specific age cohort near 80 years old.